ClinicalTrials.gg
RecruitingNCT04983199PROMPTUpdated Mar 5, 2026

Patient Reported Outcomes/Metrics Program Trial

An observational study in Metastatic Cancer and Palliative, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Neoplasm Metastasis by University Health Network, Toronto — 10 open to participants now, 15 under way, 2 of them phase 3. Neoplasm Metastasis · University Health Network, Toronto.

Started
2022
with 1 other
Observational
9 of 36
4 open now
Primary completion
2027-09
later than 7 of 14 live
Registered
27th of 36
by date

Among the 36 studies in Neoplasm Metastasis by University Health Network, Toronto, this one is one of 2 that started in 2022, is one of 9 observational ones, reaches primary completion later than 7 of the 14 other live ones, and was the 27th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 36 studies in Neoplasm Metastasis by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Neoplasm Metastasis by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is an observational study to investigate if it is feasible to recruit 100 patients receiving radiotherapy (RT) to metastatic disease to wear Hexoskin and if Hexoskin will facilitate the monitoring, detection and early treatment of RT-related side effects.

Read the detailed description

Radiotherapy is an important adjunct in the interdisciplinary care of the palliative patient population, providing the potential for improved quality of life and symptom control, often translating into improved well-being, function and mobility. Changes in pain and QOL are frequently measured subjectively using patient-reported questionnaires. Objective measures such as respiratory rate, pulse rate, activity level and sleep duration and quality, may complement the currently available tools. Such tools may lead to better evaluation of the effects of palliative RT with real-time detection of potential complications and toxicity and the acute need for analgesic adjustments that can result from successful palliative RT.

03

Conditions studied

  • Metastatic Cancer
  • Palliative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients planned for palliative radiotherapy to metastatic disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned to receive palliative radiotherapy for pain
  • Known cancer diagnosis
  • Able to wear Hexoskin Medical Shirt
  • Ability to use and populate the mobile app (Zamplo) with or without assistance
  • : 0-3
  • Willing to provide a list of analgesic (pain relief) medication
  • Willing to complete questionnaires
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Receiving whole brain radiotherapy
  • Major cognitive or psychiatric impairments
  • Pregnant women
  • Allergies to: polyester, synthetic fibers
  • Patients with pacemakers or implantable cardioverter-defibrillator (ICD)
  • Patients on a Holter Monitor
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • DeviceHexoskin Medical System

    Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.

    Also known as: Hexoskin Smart Shirt

06

What researchers measure

Primary outcomes

  1. Rate of patient accrual

    Feasibility of accruing 100 patients to the study

    Time frame: Over 12 months

  2. Frequency of radiotherapy related adverse events

    Frequency of grade 2 or above radiotherapy related adverse events with extended monitoring.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Quality Adjusted Life Years (QALY)

    Perform economic and health technology assessment using EuroQol-5 Dimension-5 Level (EQ-5D-5L) health questionnaire. (100 is the best health a patient can imagine while 0 is the worst health a patient can imgaine.)

    Time frame: Baseline to 12 months

  2. Health Related Quality of Life (QOL)

    Perform Health Related Quality of Life using EORTC QLQ-C30 and rate electronic survey completion.

    Time frame: Baseline to 12 months

  3. Number of Trial Refusals

    Evaluate reasons for trial refusal

    Time frame: Baseline to 12 months

  4. Complete follow-ups

    Rate of completed follow-ups

    Time frame: Baseline to 12 months

  5. Patient experience and satisfaction

    Measure patient experience and satisfaction using mobile app (Zamplo) and Hexoskin

    Time frame: Baseline to 12 months

  6. Patient Adherence

    Patient adherence to using the Hexoskin Medical System

    Time frame: Baseline to 12 months

  7. Hexoskin data collection rates

    Feasibility of data collection using the Hexoskin Medical System

    Time frame: Baseline to 12 months

  8. Quality of Life (QOL) survey completion

    Rate of Quality of Life (QOL) survey completion on mobile app (Zamplo)

    Time frame: Baseline to 12 months

  9. Overall survival of participants

    Overall survival time is calculated from study enrollment to date of death or last follow-up

    Time frame: Baseline to 12 months

  10. Characterize adverse event profile

    Characterize adverse event profile of various radiotherapy regimens given for metastases

    Time frame: Baseline to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Othman H, Hannon B, Liu ZA, Raman S, Sexton E, Kasper C, Auger H, Tsai CJ, Barry A, Wong P. Patient Reported Outcomes/Metrics Program Trial (PROMPT)-palliative radiation: protocol of a prospective observational feasibility study. Ann Palliat Med. 2025 Nov;14(6):570-578. doi: 10.21037/apm-25-19. PubMed 41360655 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Sep 2027, 58 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 58 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2021
First posted
Jul 30, 2021
StartActual
Nov 24, 2022
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04983199
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Nov 24, 2022
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Philip Wong
Contact
philip.wong@rmp.uhn.ca
416-946-4501 ext. 2126
Philip Wong
principal investigator · The Princess Margaret Cancer Foundation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion